

Robotic reconstruction for benign upper urinary tract obstruction: a review of the current literature

Rebeca Gonzalez Jauregui^{ID}, Rohan G. Bhalla, Karen Doersch and Brian J. Flynn

Ther Adv Urol

2025, Vol. 17: 1–22

DOI: 10.1177/
17562872251326785

© The Author(s), 2025.
Article reuse guidelines:
sagepub.com/journals-
permissions

Abstract: The field of reconstructive urology has seen a paradigm shift in the surgical approach for intra-abdominal cases, resulting in an increased preference for minimally invasive techniques. The introduction of the surgical robot has led to exponential growth in innovative approaches, reflecting the ongoing efforts to improve patient outcomes and address the limitations of open and laparoscopic surgery. This review article summarizes the knowledge gained in the last 10 years about adult robotic ureteral reconstruction. A non-systematic literature review was conducted on February 18, 2024 using Medline, PubMed, Web of Science, and Embase libraries. Studies published in English since 2014 reporting at least five robotic ureteral reconstructive cases for the management of benign ureteral obstruction in adults were included. A narrative review focusing on robotic ureteral reconstructive techniques, their associated success and complication rates, and how the robotic approach compares to open and laparoscopic reconstruction was performed. The current literature demonstrates increased utilization of the robotic platform in reconstructive urological procedures. Robotic surgery has been shown to be associated with shorter learning curves, lower surgeon fatigue, better visualization and equivalent results to those seen with laparoscopic surgery. While the literature is limited by a lack of comparative data, well-designed randomized controlled trials, and standardized criteria for defining and measuring success, this review demonstrates the safety, feasibility, and efficacy of robotic ureteral reconstruction for managing benign ureteral strictures, confirming it as a viable alternative to open and laparoscopic surgery.

Keywords: robotics, ureteral obstruction, ureteral reconstruction, ureteral stricture

Received: 29 July 2024; revised manuscript accepted: 19 February 2025.

Introduction

Upper urinary tract obstruction can arise from either benign or malignant etiologies, with an array of underlying diagnoses such as kidney stones, retroperitoneal fibrosis, endometriosis, iatrogenic injury, trauma, stricture disease, cancer, or radiation sequelae.¹ Ureteral stricture disease comprises a significant portion of upper urinary tract obstruction in adults.¹ Strictures can be managed endoscopically and with major reconstructive surgery. The exact surgical approach and technique employed for treating ureteral stricture disease often depends on factors such as length,

location, and etiology of the stricture, as well as patient and surgeon preference.¹ Until the introduction of laparoscopic surgery to reconstructive urology in the 1990s, the gold standard for treating ureteral stricture disease had been open ureteral reconstruction.² Laparoscopic surgery, however, soon became the preferred approach for managing specific urologic conditions. It resulted in lower estimated blood loss (EBL), reduced rates of complications, and shorter hospital length of stay (LOS).^{3,4} The introduction of the robotic platform with the Da Vinci Surgical System® (Intuitive Surgical, Sunnyvale, CA, USA) in the

Correspondence to:
Rebeca Gonzalez Jauregui
Division of Urology,
Department of Surgery,
Anschutz Medical Center,
University of Colorado,
Academic Office One Bldg,
12631 East 17th Ave., Box
C319, Room L15-5602,
Aurora, CO 80045, USA
rebeca.gonzalezjauregui@CUAnschutz.edu

Rohan G. Bhalla
Karen Doersch
Brian J. Flynn
Division of Urology,
Department of Surgery,
Anschutz Medical Center,
University of Colorado,
Aurora, CO, USA

early 2000s addressed many of the limitations of laparoscopic surgery, namely offering superior image quality and visualization, the option for additional visualization aids like Indocyanine green (ICG) and Firefly technology, and increased degree of motion without sacrificing surgeon ergonomics.^{2,5}

In 20 years, reconstructive urology has trended toward minimally invasive techniques.⁴ The introduction of the surgical robot sparked the birth of many novel ureteral reconstructive methods and the adaptation of surgical approaches used during open or laparoscopic surgery to the robotic platform. This review article aims to summarize the knowledge gained in the past ten years about robotic ureteral reconstruction for managing ureteral strictures, focusing on surgical technique, success, complication rates, and how the robotic platform compares to open and laparoscopic ureteral reconstruction.

Anatomy

The ureter is a retroperitoneal tubular structure that drains urine from the kidney into the bladder (Figure 1). In adults, it can measure between 22 and 30 cm.⁶ It is anatomically and functionally divided into three segments: abdominal, pelvic, and intramural. The abdominal ureter starts at the ureteropelvic junction (UPJ) and travels anterior to the psoas muscle until it reaches the brim.⁶ The pelvic ureter crosses over the bifurcation of the iliac vessels and descends anteriorly to the internal iliac artery along the lateral wall of the pelvis.⁶ The intramural ureter is the segment of the ureter that pierces the bladder at the ureterovesical junction (UVJ).⁶ The ureter has three areas of physiologic narrowing: the UPJ, as it crosses the iliac vessels, and the UVJ.⁶ These are potential sites for obstruction secondary to renal calculi.

The blood supply to the abdominal ureter comes medially from branches of the renal artery and posteriorly from the common iliac artery.⁶ Branches from the superior vesical artery supply the lateral aspect of the pelvic ureter.⁶

Etiology

In adults, obstruction of the upper urinary tract is often a result of ureteral stricture disease, which can be classified as iatrogenic, benign, idiopathic,

or malignant.¹ Although it is hard to assess the definitive incidence of ureteral strictures in the general population, it has been suggested that 35% of strictures reported in the literature are due to iatrogenic causes, of which 70% result from gynecologic surgery.¹ Ureteral injury most commonly occurs at the pelvic brim, particularly in women, where the pelvic ureter crosses under the uterine vessels and passes anterior to the vaginal fornix before reaching the bladder.⁶ Another 35% of strictures are benign, resulting from stones, infection, retroperitoneal fibrosis, endometriosis, aortic abdominal aneurysm, or trauma. Lastly, in a comprehensive review of the literature, Tyritzis and Wiklund¹ reported that the incidence of idiopathic and malignant obstruction are around 20% and 10%, respectively. While we acknowledge that these figures do not account for 100% of causes of malignant obstruction, this represents an active area of research and more work is needed to definitively examine the causes.

Pre-operative planning

Appropriate diagnostic workup is crucial when there are concerns for a ureteral stricture. It allows the surgeon to assess the need for prompt endoscopic intervention to preserve renal function, rule out malignancy, and aid in surgical planning. CT urography and antegrade or retrograde pyelogram are most commonly utilized to define stricture location and length.^{1,7} Providers can also obtain a nuclear medicine renal scan before intervention to determine baseline renal function and guide management. Traditionally, kidneys contributing less than 15%–20% of total function are not preserved as they are unlikely to have reasonable outcomes from a repair.⁸ However, pre-operative assessment should also incorporate renal volume, functional urine output, and patient-reported symptoms to guide decision-making, as functional imaging alone may not reliably determine candidacy for reconstructive intervention.⁹

Lastly, an important consideration in pre-operative planning is the use of ureteral rest before robotic ureteral reconstruction. Lee et al.¹⁰ demonstrated that patients who underwent ureteral rest—defined as the absence of internal hardware such as a stent or percutaneous nephroureterostomy tube across the stricture for at least 1–4 weeks prior to surgery—had significantly higher success rates in the repair of proximal or middle ureteral strictures compared to those who did not undergo

this practice (90.7% vs. 77.5%, $p=0.027$). The authors hypothesized that allowing the ureter to rest can promote the maturation and stabilization of the stricture, leading to clearer delineation of stricture characteristics and potentially a more successful repair.¹⁰ While the exact timing and indications for ureteral rest remain unclear, further research is necessary to understand its biological and radiographic impact and to establish more definitive guidelines regarding its optimal use.

Surgical determination

The choice of management for ureteral strictures and their associated success rates is dependent on the etiology, location, and length of the stricture. Generally, endoscopic treatments are used as first-line management for benign strictures. There are, however, several factors that are considered relative contraindications to endoscopic intervention due to their poor success rates, including long (>2cm) or ischemic strictures, a poorly functioning ipsilateral kidney, and obstruction due to extrinsic compression.¹ When endoscopic approaches are not an option due to previously failed intervention or contraindication, ureteral reconstruction is recommended via an open, laparoscopic, or robotic approach.

The etiology of strictures is a critical determinant in selecting the optimal treatment strategy. For instance, radiated strictures often require more nuanced management because of their ischemic nature and the surrounding tissue damage.¹¹ These strictures are less likely to respond to endoscopic treatments and frequently necessitate surgical reconstruction, with ureteral reimplantation or ureteral substitution often preferred.¹¹ Additionally, strictures resulting from recurrent infections or malignancies may require tailored approaches depending on the broader clinical context.

The choice of surgical technique is often determined by stricture location (Figure 1). Abdominal or upper ureteral strictures are managed with either pyeloplasty, ureterocystostomy (UC), ureteroplasty, ureteroureterostomy (UU) or transureteroureterostomy (TUU).^{3,12} Distal strictures are usually managed with ureteral reimplantation (UR) with or without adjunct mobility procedures such as a psoas hitch (PH) or Boari flap (BF).^{3,12} Complex or pan-ureteral strictures not amenable to other methods of ureteral repair can be managed with intestinal substitution or renal auto-transplantation.³




Figure 1. Anatomic rendition of the kidney, ureter, and bladder with depiction of reconstructive techniques by stricture location and length: findings from a narrative review.

Moreover, one of the guiding principles of ureteral reconstruction is the need for a tension-free anastomosis. Therefore, the length of the stricture can limit surgical options, as is the case with UUs, which are usually recommended for strictures measuring ≤ 3 cm.^{1,12} For distal strictures located ≥ 5 cm from the ureteral orifice, UR should be performed by adding a PH or BF.¹² Lastly, it is important to remember that bladder function is another critical factor in determining surgical management. Reconstructive techniques, such as UR with a PH or BF, often depend on a well-functioning bladder to achieve successful outcomes.⁸ In patients without suspected underlying causes of bladder dysfunction, a uroflow and post void residual assessment is likely sufficient; patients with underlying bladder conditions may benefit from formal urodynamics to assess capacity and compliance. Patients with impaired bladder compliance or capacity, often secondary to prior radiation or neurogenic bladder dysfunction, may not tolerate increased bladder demands imposed by reimplantation techniques.⁸ In these cases, more extensive reconstructive strategies may be required.

Methods

A comprehensive narrative review of the literature was performed on February 18, 2024 on MEDline, PubMed, Web of Science, and Embase databases using the following search terms: (“ureteral reconstruction” OR “ureteric reconstruction” OR “pyeloplasty” OR “ureteroureterostomy” OR “ureteroneocystostomy” OR “ureterocalycostomy” OR “ureteral reimplant” OR “ureteral implant” OR “ureteric reimplant” OR “ureteroplasty” OR “transureteroureterostomy” OR “kidney auto-transplantation” OR “kidney auto transplantation” OR “intestinal interposition”) AND (“ureteral obstruction” OR “ureteric obstruction” OR “obstruction” OR “stricture” OR “ureteral stenosis” OR “ureteric stenosis” OR “ureteral stricture” OR “ureteric stricture” OR “upper ureter*” OR “lower ureter*” OR “distal ureter*” OR “mid ureter*” OR “proximal ureter*”) AND (robotic* surgery OR “robotic assisted” OR “robotic” OR “robot” OR “robot assisted” OR “robot-assisted”) AND (“adult*” OR “young adult”) NOT (“children” OR “child” OR “pediatric” OR “paediatric” OR “peds” OR “kid*” OR “infant*” OR “neonate*”).

Study eligibility was defined by the PICOS framework: population (P), intervention (I), comparator (C), outcome (O), and study design (S).

Studies that fulfilled the following criteria were included for analysis: (P) adult patients (≥ 18 years old) who underwent a ureteral reconstructive surgery for the treatment of benign ureteral obstruction; (I) robotic ureteral reconstructive surgery; (C) non-robotic surgical intervention including endoscopic management, open, or laparoscopic surgery (O) peri- and post-operative outcomes, complications, follow-up time and success rates; (S) randomized-controlled trials (RCTs), non-randomized cohort studies, and meta-analyses. Exclusion criteria included publication date before 2014, non-English publications, studies with a follow-up period of less than 12 months, studies with fewer than five robotic cases of any singular ureteral reconstructive technique and studies reporting multiple techniques without providing individual outcomes for each technique. Reviews, conference abstracts, letters, commentaries, and editorials were excluded from the analysis. Articles were reviewed for relevance by the authors (RGJ and RGB), who excluded articles based on the title, followed by the abstract, and finally, the full text. Reference lists of included manuscripts were also screened for eligibility. Each reviewer worked independently. The article selection process is depicted in Figure 2.

Surgical management

Pyeloplasty

Ureteropelvic junction obstruction (UPJO) in adults can result from congenital anomalies that affect the ureters, including peristaltic ureteric segments, ureteral kinking, and duplex systems, as well as vascular anomalies, as is the case with crossing vessels.¹³ More often, UPJO in adults results from acquired causes such as renal calculi, iatrogenic injury, or malignancy.¹³

While endoscopic management is often the first-line treatment for patients with UPJO, their associated failure rates are significantly higher than those of definitive surgery, leading to a slight decrease in its utilization in recent decades.^{14–16} Options for surgical management of UPJO include Anderson-Hynes dismembered pyeloplasty and dismembered pyeloplasty with renal pelvis U-flap, as well as non-dismembering options such as Y-V and Fenger pyeloplasty.^{13,17} The Anderson-Hynes technique has been the preferred option for the last century, given its adaptability in addressing various reasons for UPJO and its excellent outcomes. Recent comparative studies have




Figure 2. Study selection flow chart.

consistently shown success rates exceeding 90% across all three surgical modalities (robotic, laparoscopic, and open), further reinforcing its efficacy (Table 1).^{18–20}

While open pyeloplasty has historically been considered the gold standard for the definitive management of UPJO, it was noted that from 2002 to 2010, there was a 40% decrease in its use among American urologists.¹⁵ This drop in open pyeloplasties and increased utilization of minimally invasive surgery (MIS) has been driven by the comparative success rates offered by MIS and its superior perioperative outcomes, such as decreased EBL and pain scores, lower risk of postoperative complications and shorter LOS (Table 1).^{15,16,18,19,21}

Compared to the laparoscopic approach, robotic-assisted laparoscopic (RAL) pyeloplasty offers similar success rates and functional outcomes; however, it has been shown to result in shorter

operative times, lower surgeon fatigue, and a shorter learning curve of 20–30 cases.^{18,19,22–24} For these reasons, RAL pyeloplasty has become an attractive and reasonable alternative to treating both primary and recurrent UPJO.^{17,25–39} RAL pyeloplasty has also been shown to be an effective and safe option for the management of complex cases of UPJO due to concomitant congenital anomalies such as horseshoe kidney, duplex systems and malrotated kidneys.⁴⁰

A key advantage of the robotic surgical approach is the ability to employ ICG to assess tissue perfusion and urinary tract patency. ICG can be administered intravenously and will demonstrate perfusion of flap tissue, including tissues being used for intestinal interposition or flaps, such as omental flaps, being used to support the repair. Furthermore, instillation of ICG into the ureter can aid in identification of the patent portions of the urinary tract. One downside of intraluminal

Table 1. Summary of selected studies describing robotic management of ureteral strictures at the level of the UPJ.

Author	Year	Cases (n)	Platform	Technique	OT (min)	EBL (mL)	LOS (days)	CD < 3 (n)	CD ≥ 3 (n)	Complications described	Follow up (months)	Success (%)
Basatac et al.	2014	56	RAL (15)	Pyeloplasty	114	28*	2*	1	0	Erythrocyte transfusion (1)	36	93.3
			LAP (16)		130	31*	2.8*	1	0	UTI (1)	12	93.75
			Open (25)		127	105*	4.14*	5	0	Anastomotic leak (3), wound site infection (2)	40	%
Pahwa et al.	2014	90	RAL (30)	Pyeloplasty	141.73*	46.37*	2.45*	na	na	na	13.5	96.7
			LAP (30)		191.56*	55.24*	3*				18	96.7
			Open (30)		127.5*	114.47*	4.83*				35	93.3
Carmona et al.	2022	65	RAL (41)	Pyeloplasty	242.4*	50	3.3*	7	2	Anastomotic leak (6), hematuria (1), UTI (2)	19	90.6
			LAP (24)		161.4*	36	7.3*	4	2	Anastomotic leak (4), hematuria (1), UTI (1)	85.2	87.5
Cheng et al.	2021	21	RAL (8)	Flap pyeloplasty	142.4	66.3	5*	0	0		12.6	100
			LAP (13)		179.1	58.5	8.2*	2	0	UTI (2)	21.2	84.6
Cheng et al. ^a	2021	53	RAL (20)	Renal pelvis flap onlay ureteroplasty (11)	157.5*	50	5.5*	na	na	na	12.8	100
			LAP (33)	Renal pelvis flap onlay ureteroplasty (17)	191.6*	30	8.6*					88.2
Fiori et al.	2017	27		Pyeloplasty								
			SP RAL (15)		190*	na	3	2	0	Fever (1), urine leak (1)	44	100
			mini LAP (12)		128*			1	0	Fever (1)	81	87.5
												91.7
Heo et al. ^a	2023	39	SP RAL	Pyeloplasty (18)	152	8	3	0	1	UTI (1)	18.5	100
												94.4
Buffi et al.	2015	30	SP RAL	Pyeloplasty	160	na	5	7	1	Urine leak (1)	13	93.3
Razavi et al.	2023	10	RAL	Pyeloplasty	160	50	1.5	1	0	Urine leak (1)	13	89
												100
Razavi et al.	2023	141	RAL	Pyeloplasty for symptomatic UPJO (108)	191	69	1.9	5	3	Stent encrustation (2), stent migration (1), urine leak (3), perinephric hematoma (1), gross hematuria (1)	12	92

(Continued)

Table 1. (Continued)

Author	Year	Cases (n)	Platform	Technique	OT (min)	EBL (mL)	LOS (days)	CD < 3 (n)	CD ≥ 3 (n)	Complications described	Follow up (months)	Success (%)
				Pyeloplasty for asymptomatic UPJO [33]								88
Fan et al.	2022	32	DV-RAL (16)	Pyeloplasty	118*	10	4.2	2	0	Bladder spasms (2)	19.5	100
			KD-RAL (16)		141*	8	4.3	1	0	UTI (1)	19	93.75
Whiting et al.	2022	160	RAL	Pyeloplasty	139.4	10	1	5	6	Urine leak (2), pneumothorax (1), UTI (2), wound infection (1), migrated stent (1), perirenal hematoma (1), ventilatory support (1), ureteric stent re-insertion for obstruction (1), restenosis requiring nephrostomy (1)	12	94.5
Popelin et al.	2021	214	RAL	Pyeloplasty	110	<100	3	21	9	Urinoma (13), infection (15), hematoma (2)	14	91.4
Lee et al.	2020	158	RAL	Primary pyeloplasty (130)	136*	50*	1	na	5	Abdominal abscess (1), myocardial infarction (1), port site infection (1), stent migration (2).	21.1	92.3
				Secondary pyeloplasty (28)	188.0*	100*		na	0		20.3	85.7
Dirie et al.	2020	114	RAL	Primary pyeloplasty (96)	na	137	6	14	7	na	25	94.8
				Secondary pyeloplasty (13)		148	6	2	1			76.9
Masieri et al. ^a	2019	36	RAL	Pyeloplasty (24)	160	na	6	2	1	na	17	83.3
Masieri et al.	2019	292	RAL	Pyeloplasty	112.8	na	4	28	1	Allergic reaction (1), COPD exacerbation (1), hypertension (1), pneumonia (2), fever (6), wound infection (6), sub-ileus (4), abdominal pain (3), bleeding (4), blood transfusions (2), stent migration (1)	21	98

(Continued)

Table 1. (Continued)

Author	Year	Cases (n)	Platform	Technique	OT (min)	EBL (mL)	LOS (days)	CD < 3 (n)	CD ≥ 3 (n)	Complications described	Follow up (months)	Success (%)
Chammas et al.	2019	100	RAL	Pyeloplasty	118	<100	5.23	2	2	Stent migration (2), pyelonephritis (2)	50.6	98.9
Wood et al.	2018	83	RAL	Pyeloplasty	148	32.1	2.7	9	3	Small bowel injury (1), dyspnea (1), chest pain and collapse (1), confusion (1), anuria (1), delayed wound healing (1), infection (1), chest infection and ileus (1), vomiting, constipation and abdominal pain (1), anastomotic leak (2), stent blockage (1)	23.1	95.6
Jensen et al. ^b	2017	74	RAL	Pyeloplasty + pyelolithotomy (18)	151*	20	3	3	0	Postoperative infection (2), polyuria (1)	12	66.7
Buffi et al. ^a	2017	183	RAL	Pyeloplasty (145)	120	na	4.7	10	2	Urine leak (1), stent migration (1)	24	92.5
Hopf et al.	2016	129	RAL	Pyeloplasty	245.8	29.5	2	8	10	Urine leak (9), UTI (5)	33.8	96.9
Lamb et al.	2015	20	RAL	Pyeloplasty	203	<200ml	2.8	1	0	Port site hematoma (1)	14	95
Lee et al. ^a	2015	26	RAL	Pyeloplasty (8)	154.9	49.4	1.4	na	na	na	12	100
Marlen et al. ^{a,b}	2015	250	RAL	Pyeloplasty + stone extraction (19)	224.8	79.2	2.8	3	3	na	15	85
Di Gregorio et al.	2014	17		Pyeloplasty	180	14	5.29	0	2	Urine leak (2)	25.77	94
Ramanitharan et al.	2020	6	RAL	UC	178	115	6.1	2	0	Fever (1), UTI (1)	15	100

^aData from this study regarding reconstructive techniques not relevant to this table has been omitted.^bData from this study with less than 12 months FU has not been included in this table.**p* ≤ 0.05.

CD, Clavien Dindo Score; COPD, chronic obstructive pulmonary disease; DV-RAL, da Vinci Si Surgical Robot; EBL, estimated blood loss; KD-RAL, Kangduo Surgical Robot; LAP, laparoscopy; LOS, length of stay; na, not available; OT, operative time; RAL, robotic-assisted laparoscopy; SP, single port; UC, ureterocalicostomy; UPJ, ureteropelvic junction; UTI, urinary tract infection.

ICG use is that spillage after opening the patent portion of the urinary tract can make it difficult to interpret further ICG usage.³²

While RAL pyeloplasty is more commonly performed through transperitoneal access, one author set out to explore the safety and efficacy of performing RAL pyeloplasty through a retroperitoneal approach. In this study, Whiting *et al.* found retroperitoneal RAL pyeloplasty to have success rates of 94.5%.⁴¹ However, the authors reported that retroperitoneal RAL pyeloplasty has a longer learning curve and operative times.⁴¹ The authors advise that while the retroperitoneal approach offers many benefits, its utilization should be based on a surgeon's comfort level and training.

It has been estimated that approximately 20% of patients with UPJO will present with concomitant stones. However, the current literature lacks consensus on the superior management mode for stone burden during pyeloplasty. A few recent retrospective single-center studies explored the role of concurrent stone extraction at the time of RAL pyeloplasty to manage concomitant calculi.^{25,42} Notably, Marien *et al.*²⁵ found that patients who underwent pyeloplasty with stone extraction had statistically significant decreased rates of radiographic improvement (87%), as compared to those who underwent pyeloplasty alone and had 99% improvement. These results of this study, while important to consider, are limited by a lack of specification of the technique used to remove stones.

Another area of increased interest in the recent literature has been the adoption of the Da Vinci Single-Port (SP)[®] system (Intuitive Surgical, Inc.) for the management of UPJO, which is a safe and effective alternative to other more mainstream approaches.^{43–45} By minimizing the number of entry points into the abdomen, using the SP system could potentially decrease post-operative pain, recovery time, and wound-related complications while providing better cosmetic results.^{43–45} While all articles cited in our review reported using intraperitoneal access, a major advantage of the SP system lies in its capability for retroperitoneal access. This approach offers significant benefits, particularly for patients with prior abdominal surgeries or a history of abdominopelvic radiation. Retroperitoneal access with the SP system is also advantageous for obese patients, as it avoids the need for complex

positioning by allowing them to remain supine during the procedure. This is possible due to the SP's wide external range of motion, enabling complete 360° anatomical accessibility, which allows surgeons to change the target organ and perform additional procedures without requiring redocking of the robot or repositioning of the patient.

In a multicenter prospective study of SP pyeloplasty, Buffi *et al.*⁴³ reported a 93.3% success rate at 13 months of follow-up and minimal complications. The authors noted some potential limitations of the SP system, including instrument crowding and limited triangulation.⁴³ A single-center retrospective comparative study between SP pyeloplasty and mini-laparoscopic pyeloplasty found both approaches to offer similar results in post-operative narcotic usage and cosmetic satisfaction.⁴⁵ In this study, SP pyeloplasty was associated with longer operative times and a significantly higher cost, which could be potential limitations to its adoption.⁴⁵

Ureterocalycostomy

Ureterocalycostomy (UC) is another option for treating UPJO, usually reserved for instances of previously failed pyeloplasty or a relatively inaccessible renal pelvis.⁴⁶ This technique has yet to be widely adopted to the robotic platform, as many surgeons prefer the open approach due to the complexity of this technique. A small case series reported using RAL UC to manage secondary UPJO with minimal complications and success rates of 100% at 15 months follow-up.⁴⁶ Ramanitharan *et al.*⁴⁶ reported using near-infrared fluorescence (NIRF) with Firefly technology during RAL UC to avoid complications related to recurrent obstruction and anastomotic stricture.

Ureteroureterostomy

Ureteroureterostomy (UU) is most commonly used for short strictures (≤ 3 cm) located in the upper ureter. RAL UU offers low complication rates and success rates ranging from 83.3% to 100% at short to intermediate-term follow-up (Table 2).^{25,26,32,47–50} A retrospective single-center comparative study by Sun *et al.*⁴⁷ found significantly lower operative and suturing times, as well as shorter LOS in the robotic group as compared to the laparoscopic group, making this a safe and effective alternative to conventional laparoscopy.

Table 2. Summary of selected studies describing robotic ureteroureterostomy for the management of ureteral strictures.

[illegible]

RAL UU has also been found to be a suitable option for treating longer strictures in the upper ureter measuring up to 4 cm as well as complex, recurrent, and iatrogenic strictures.^{25,26,48,49} The use of downward nephropexy to gain 3–5 cm of ureteral mobilization and attain tension-free anastomoses can aid in these cases.⁵¹ Moreover, RAL UU has also been shown to be helpful in distal strictures, contradictory to popular belief.^{47,49} Yang *et al.* recently described the use of RAL UU for the management of short distal strictures in 137 young, healthy adults with no history of abdominopelvic radiation. They managed short strictures (1–2 cm) with a 90.1% success rate at a median follow-up time of 54.6 months.⁴⁹ The authors used NIRF with intravenous ICG during dissection to identify and spare the tenuous blood supply to the distal ureter.⁴⁹

Ureteroplasty

Graft ureteroplasty is often employed for the management of upper ureteral strictures measuring more than 1.5 cm as well as complex and recurrent ureteral strictures that would otherwise require management with ileal ureteral interposition or auto-transplantation, which carry a high degree of morbidity and are much more technically challenging.^{52,53} Ureteral rest in this context may be beneficial to more accurately define the length and caliber, thereby aiding in graft or flap selection.¹⁰ The most commonly used grafts for the management of ureteral strictures include buccal and lingual grafts.^{39,51,52,54,55} An essential distinction between grafts and flaps, which can also be used to manage ureteral strictures, is that a graft is made of tissue that does not contain its blood supply and, upon transfer to the recipient site, will develop a new blood supply. In contrast, a flap is a vascularized tissue that maintains blood supply after being transferred to the recipient site.⁵³

The high success rate associated with the use of buccal mucosal graft (BMG) in urethroplasties led to its adoption for the treatment of ureteral strictures. RAL BMG ureteroplasty is safe and effective for managing upper ureteral strictures and recurrent, complex, or lengthy strictures resulting in low complication rates and success rates ranging between 72.7% and 92.9% at intermediate-term follow-up (Table 3).^{51,52,55} Moreover, two multi-institutional retrospective studies found RAL BMG ureteroplasty effective

for managing recurrent long-segment UPJO or UPJO with significant surrounding fibrosis with success rates over 80%.^{17,52} Using omental flaps wrapped over the BMG graft has been described to ensure graft survivability and reduce the risk of stricture recurrence.⁵⁶

While the number of studies on using lingual mucosal graft (LMG) during RAL ureteroplasty is limited, recent reports demonstrate excellent outcomes with success rates over 90%.^{39,54} Consistent with the previous reports comparing robotic and laparoscopic approaches, RAL LMG ureteroplasty resulted in shorter operative times and LOS.^{39,54} Lastly, while the proposed benefits of LMG include lower donor site morbidity, this review found both BMG and LMG RAL ureteroplasty to have minimal donor site-associated complications.^{39,51,52,54,55} Currently, there is no consensus on which type of graft is superior or if there are specific scenarios where one type of graft should be picked over another.

Transureteroureterostomy

While transureteroureterostomy (TUU) is not a commonly performed procedure, it is typically used in adults undergoing multi-organ resection for malignancy or treating mid-ureteral strictures not amenable to other reconstructive techniques.¹² TUU is contraindicated in patients with urothelial carcinoma of the ureter, idiopathic retroperitoneal fibrosis, renal stones, and a history of pelvic radiation or ureteral stricture disease in the recipient ureter.¹² No studies were found on RAL TUU that fit our search criteria.

Ureteral reimplantation

Recent comparative studies have demonstrated that managing distal ureteral strictures with RAL UR, also known as ureteroneocystostomy (UNC), has similar success rates to open and laparoscopic UR (Table 4).^{57–61} Moreover, compared to the open approach, RAL UR has been shown to offer superior results in EBL, operative times, and LOS.^{57–60} In an analysis of an extensive prospective multicenter national database, Packiam *et al.* found that in the first 30 days after UR, patients who underwent open surgery were significantly more likely to experience complications related to wounds and infection than patients who underwent MIS.⁵⁷ Despite the clear advantages of MIS over open surgery, data from the National Surgical Quality Improvement Program Database

Table 3. Summary of selected studies describing robotic ureteroplasty for the management of ureteral strictures.

Author	Year	Cases (n)	Platform	Stricture location	Technique	OT (min)	EBL (mL)	LOS (days)	CD < 3 (n)	CD ≥ 3 (n)	Complications described	Follow up (months)	Success (%)
Fan et al.	2023	32	RAL (16)	na	LMG ureteroplasty	192*	na	6.1*	3	0	Tongue numbness (1), parageusia (1), UTI (1)	21	93.75
Cheng et al. ^a	2021	53	RAL (20)	Upper	LMG onlay ureteroplasty (5)	201.8	30	5.6	na	na	na	12.8	80
Lee et al. ^{a,b}	2023	105	RAL	Mid	BMG ureteroplasty (8)	209.5	100	1	na	0	na	39.9	75
Lee et al. ^a	2021	20	RAL	Proximal	BMG ventral ureteroplasty (14)	272	100	2	na	1	Gluteal compartment syndrome (1)	24	92.9
Lee et al.	2021	54	RAL	Upper	BMG onlay (43) BMG augment (11)	222.5	75	1	na	3	Hernia (1), re-intubation (1), gluteal compartment syndrome (1)	27.5	90.7 72.7

^aData from this study regarding reconstructive techniques not relevant to this table has been omitted.^bData from this study with less than 12 months FU has not been included in this table.**p* ≤ 0.05.

BMG, buccal mucosal graft; CD, Clavien Dindo Score; EBL, estimated blood loss; LAP, laparoscopy; LOS, length of stay; na, not available; OT, operative time; RAL, robotic-assisted laparoscopy; UTI, urinary tract infection; UU, ureteroureterostomy.

Table 4. Summary of selected studies describing robotic ureteral reimplantation for the management of ureteral strictures.

Author	Year	Cases (n)	Platform	Stricture location	Technique	OT (min)	EBL (mL)	LOS (days)	CD < 3 (n)	CD ≥ 3 (n)	Complications described	Follow up (months)	Success (%)
Carbonara et al.	2021	48	RAL (21)	Mid, Distal	UNC	216*	35*	2*	7	0	Urinary retention (2), acute kidney injury (1), urine leak (1), UTI (3)	97	100
			Open (28)			317*	175*	6*	12	1	Lymphocele (1), acute kidney injury (1), urine leak (2), fever (3), ileus (2), UTI (1), transfusion (3)	155	100
Skupin et al.	2020	45	RAL (18)	Mid (1), Distal (17)	UNC	195	50*	1.5*	6	1	na	14.1	100
			Open (27)	Mid (6), Distal (21)		209.6	100*	3*	7	2		19.9	96.3
Elsamra et al.	2014	130	RAL (20)	na	UNC	236	100*	2*	na	2	na	16.6	90
			LAP (85)			235	150*	3*	na	10			94
			Open (25)			257	300*	5*	na	5			84
Zhang et al.	2020	62	RAL (28)	Distal	UNC	146.4*	na	5.54	3	0	Fever (3)	27.47	89.3
			LAP (34)			185.4*		5.74	4	0	Fever (2), hypoproteinemia (2), urinary leak (1)	28.08	82.4
Heo et al. ^a	2023	39	SP RAL	Distal	UNC (21)	152	10	3	0	2	Colonic serosal tear (1), stent migration (1)	15	100
Corse et al. ^a	2023	50	RAL (46)	Upper (22), Distal (26)	UNC + BF	231	50	2	na	3	Urinoma (1), pseudoaneurysm (1), colovesical fistula (1)	15	90
Lee et al. ^a	2023	105	RAL	Distal	Side-to-side UNC (7)	184.5	50	2	na	0		19.1	100

(Continued)

Table 4. (Continued)

Author	Year	Cases (n)	Platform	Stricture location	Technique	OT (min)	EBL (mL)	LOS (days)	CD < 3 (n)	CD ≥ 3 (n)	Complications described	Follow up (months)	Success (%)
Asghar et al. ^a	2021	35	RAL	Mid (2), Mid-distal (7), Distal (22)	End-to-end UNC (26)	215	100	2	na	2	Small bowel leak (1)	13	90.4
					End-to-end UNC (21)								
Dell'Oglio et al.	2021	37	RAL	Distal	Side-to-side UNC (8)	178	100	5	na	2	Urine leak (1), abdominal pain (1), transitory sensory loss of the leg (3), UTI (3), lymphocele (1), abdominal hematoma (1)	24	100
					UNC + PH (30)								
Slawin et al.	2020	16	RAL	Distal	UNC + BF (7)	214	50	1	na	0	na	12.5	93.8
					Non- transecting UNC								
Masieri et al. ^a	2019	36	RAL	Distal (12)	UNC (6)	na	na	na	na	na	na	17	100
Buffi et al. ^a	2017	183	RAL	Distal	UNC (21)	165	na	8	3	2	Hematoma (1), urinary fistula (1)	24	93.3
Stolzenburg et al.	2016	11	RAL	na	Modified BF UNC	166.8	155.5	na	na	na	Anastomotic leak (1)	15.2	100
Do et al.	2014	8	RAL	na	UNC + BF	171.9	161.3	na	1	0	Prolonged catheterization (1)	12	100
^a Data from this study regarding reconstructive techniques not relevant to this table has been omitted. * $p \leq 0.05$. BF, boari flap; CD, Clavien Dindo Score; EBL, estimated blood loss; LAP, laparoscopy; LOS, length of stay; na, not available; OT, operative time; PH, Psoas hitch; RAL, robotic-assisted laparoscopy; SP, single port; UNC, ureteroneocystostomy; UTI, urinary tract infection.													

showed that between 2007 and 2017, reconstruction of the distal ureter in 926 patients was performed using open surgery in 50.5% of cases.⁴

In patients with normal bladder function and distal strictures located more than 5 cm from the ureteral orifice, the adjunct use of a PH or BF during UR is recommended to achieve tension-free anastomosis.¹² A PH can be beneficial in strictures measuring 6–10 cm, while a BF can be used for strictures measuring up to 15 cm.^{12,62} Both techniques have been shown to offer high success rates and low rates of complications.^{11,44,58,62–65} Bladder capacity should be assessed prior to the use of BF to ensure that flap creation does not compromise bladder storage volumes. However, a significant limitation of our current understanding of the efficacy of PH and BF is that most studies report their use as part of large ureteral reconstruction cohorts that don't often differentiate outcomes by the technique used. One prospective multi-institutional study by Coarse *et al.*⁶³ reported using UR with BF in a high-risk cohort of 50 patients with a 90% success rate and minimal significant complications. Moreover, the current data on SP UR is limited to very small cohorts; Heo *et al.*⁴⁴ reported 100% success rates in five patients undergoing SP UR + PH.

A novel ureteral reconstructive technique employing a non-transecting side-to-side anastomosis described by Slawin *et al.* for managing distal strictures was found to be safe and effective.^{11,66} This approach seeks to preserve the tenuous blood supply to the distal ureter by eliminating ureteral transection and minimizing dissection.^{11,66} In a cohort of 16 patients undergoing RAL non-transecting side-to-side anastomosis, 93.8% remained stricture-free at a median follow-up time > 12 months.⁶⁶ Increased risk of symptomatic de-novo reflux is something surgeons should keep in mind when performing this technique.⁶⁶

Lastly, while managing upper ureteral strictures with UR is not standard of care, Corse *et al.* described high success rates with RAL UR + BF in 22 patients with proximal/mid strictures.⁶³ While overall, the study reported excellent outcomes, it offers readers limited insight into the results by stricture location.

Intestinal interposition and onlay

Complex ureteral strictures, including those that are proximal, long, bilateral, obliterative, or

radiated, might not always be amenable to management by the techniques above, in which case, intestinal interposition should be considered.⁶⁷ Adopting the laparoscopic and robotic platforms for intestinal interposition has been slow, likely due to technical difficulties. Nevertheless, recent studies have reported using intracorporeal and extracorporeal RAL intestinal interposition, with success rates ranging from 86.7% to 100% at a short-term follow-up and minimal significant complications (Table 5).^{68–70} In a comparative study, Zhu *et al.* found RAL ileal ureter to offer significantly reduced operative times, minimal EBL, and shorter LOS than the laparoscopic group.⁷⁰ Patients in the RAL group also had shorter recovery, as demonstrated by significantly reduced time to oral intake and drain removal.

Although the use of small and large intestinal segments has been described for upper and lower urinary tract reconstructive surgery, the ileum is usually preferred by urologists due to its rich vascular supply, good mobility, and decreased risk of associated metabolic complications compared to other intestinal segments.^{68–70} In recent years, there has been growing interest in appendiceal interposition, as the smaller surface area of the appendix makes intestinal interposition less likely to be associated with metabolic imbalances.⁷¹ Jun *et al.*⁷¹ performed RAL appendiceal interposition in five patients with obliterative strictures with no primary bowel-related complications. It has been argued that an appendiceal procedure might be a good option for patients that have an appendix, as it does not carry the donor site morbidity risk that oral mucosal grafts do, nor the metabolic complications associated with the creation of an ileal ureter and offer success rates over 90%; however, it might not be well suited for left-sided ureteral strictures, due to increased risk of anastomotic tension and intestinal volvulus.^{71–73} The length of ureteral stricture that can be treated with an appendiceal onlay is only limited by the size of the patient's appendix. In the study by Jun *et al.*⁷¹ the longest stricture treated with an appendiceal procedure measured 15 cm.

Auto-transplantation

Kidney auto-transplantation (KAT) is considered a last resort in managing complex proximal or pan-ureteric strictures, reserved for renal preservation in patients where other reconstructive procedures are contraindicated. Adapting this technique to MIS has significantly decreased morbidity and

Table 5. Summary of studies describing the management of complex strictures.

Author	Year	Cases (n)	Platform	Technique	OT (min)	EBL (mL)	LOS (days)	CD < 3 (n)	CD ≥ 3 (n)	Complications described	Follow up (months)	Success (%)
Intestinal interposition and onlay												
Fan et al.	2022	18	RAL	Extracorporeal ileal ureter	248	50	7	15	5	UTI (4), incision hernia (1), kidney stone (4), metabolic acidosis (6), incomplete ileus (4), incision infection (1)	16	100 94
Yang et al.	2023	15	RAL	Intracorporeal ileal ureter	261.8	64.7	10.5	18	0	Fever (5), ileus (3), UTI (10)	14	100 86.7
Zhu et al.	2021	35	RAL (10) LAP (15)	Extracorporeal ileal ureter	287.6	68*	9.6*	1	0	UTI (1)	14	100
Wang et al.	2022	8	RAL	Appendiceal onlay	162	78	8	2	0	Fever (1), stent migration (1)	18	100
Jun et al.	2020	13	RAL	Appendiceal onlay (8)	337	116	2.5	3	1	Death (1), ileus (1), UTI (1) wound (1)	14.6	100
Kidney auto- transplantation				Appendiceal interposition (5)								80
Kaouk et al.	2023	8	SP RAL	Extracorporeal KAT	520	143	3	na	1	Bleeding (1)	13	na
Breda et al.	2022	29	RAL	Extracorporeal KAT (15)	360	75	5	2	3	Fever/infection (2), stent dislocation (1), bleeding (1), eventration (1)	12	na
				Intracorporeal KAT (14)	307	170	5	4	1	Chyle leak (1), fever/ infection (2), deep vein thrombosis (1), leg compartment syndrome (1)		
*p ≤ 0.05. CD, Clavien Dindo Score; EBL, estimated blood loss; KAT, Kidney auto-transplantation; LAP, laparoscopy; LOS, length of stay; na, not available; OT, operative time; RAL, robotic-assisted laparoscopy; SP, single port; UTI, urinary tract infection.												

complication rates.⁷⁴ Breda *et al.* confirmed the safety and feasibility of RAL KAT in a comparative study of extracorporeal (eRAL KAT) and intracorporeal (iRAL KAT) approaches.⁷⁴ In a cohort of 29 patients, 15 underwent eRAL KAT and 14 iRAL KAT, with no statistically significant differences in perioperative outcomes and postoperative complications between the groups. Regarding functional outcomes, the eRAL KAT had significantly better preserved renal function at 90 days post-operatively (93.3% vs 57.1%, $p < 0.05$), but at 1 year, renal function in both groups was equivalent.⁷⁴ While the recent literature on using RAL KAT is promising, the widespread adoption of this technique is limited by its complexity and the need for a highly trained multidisciplinary team of transplant, urology, and vascular surgery.

Kaouk *et al.* described the feasibility of SP KAT for the management of complex strictures in a small cohort of eight patients. The mean OT was 520 min and patients had a median LOS of 3 days. The median length of follow up was 13 months, at which time the median change in glomerular filtration rate was 3.5%. The authors point out that an advantage of SP KAT is its unique ability to access multiple quadrants without the need for patient repositioning or re-docking, unlike with the multiport platform.⁷⁵

Special populations

Post-kidney transplant ureteral strictures

Ureteral strictures are common complications after kidney transplantation. While endoscopic treatment has become the initial treatment of choice for this condition, success rates are significantly lower than those achieved with open ureteral reconstruction.⁷⁶ The literature on the use of the robotic platform for the management of ureteral disease in kidney transplant patients is very limited. No studies were found on the robotic management of post-transplant ureteral strictures that fit our search criteria.

However, this is an area where the robotic platform might have a lot to offer. One of the biggest challenges of working on these types of cases is the difficulty of working through the fibrosis surrounding the graft and failure to identify the graft ureter, which could potentially be ameliorated with the use of ICG and Firefly technology.

Table 6. Summary of selected studies describing the robotic management of uretero-enteric strictures.

Author	Year	Cases (n)	Platform	Technique	OT (min)	EBL (mL)	LOS (days)	CD < 3 (n)	CD ≥ 3 (n)	Complications described	Follow up (months)	Success (%)
Special populations												
Tuderti <i>et al.</i>	2019	10	RAL	Ureteroenteric reimplantation	140	50	5	2	1	UTI (1), blood transfusion (1), bowel perforation (1)	19	90
Lee <i>et al.</i>	2019	8	RAL	Ureteroenteric reimplantation	208	125	6	3	2	ileus (1), oxygen requirement (1), urine leak (1), pulmonary embolism (1), stent migration (1)	29	80
Gin <i>et al.</i>	2017	50	Open (37) RAL (5)	Ureteroenteric anastomotic revision	218.5	75	6	14	1	leg abscess (1), DVT (1), wound infection (4), arrhythmia (4), ileus (3), PICC line infection (1), C. diff infection (1)	16.3	100
CD, Clavien Dindo Score; DVT, deep vein thrombosis; EBL, estimated blood loss; LOS, length of stay; na, not available; OT, operative time; RAL, robotic-assisted laparoscopy; UTI, urinary tract infection.												

Uretero-enteric strictures

In the case of uretero-enteric anastomotic strictures (UAS), a common complication of radical cystectomy, robotic uretero-enteric reimplantation (RAL UER) was shown to offer excellent perioperative outcomes and success rates (Table 6).^{77–79} Gin et al, reported their outcomes with both open and robotic UER and noted that the robotic groups had shorter LOS and no postoperative complications.⁷⁷ A recent meta-analysis reported that the open and robotic approaches were comparable in terms of perioperative outcomes and success rates, with the added caveat of less postoperative complications in the robotic group.⁸⁰ While reconstructed anatomy and extensive fibrosis secondary to a complex surgical and medical history in this patient population presents a challenge to the adoption of RAL UER⁸⁰; the use of intra-ureteral and intra-urinary diversion ICG during RAL UER has been reported to be an advantage of performing UER robotically, as it allows for faster identification and dissection of the UAS.^{78,79}

Limitations and future directions

From the available data, several key insights can be drawn about the role of robotics in upper urinary tract reconstruction. Robotic surgery has proven to be both safe and effective for ureteral reconstruction, with demonstrated benefits such as reduced blood loss, shorter hospital stays, and quicker recovery times compared to traditional open techniques. These advantages, coupled with increased utilization and successful outcomes, suggest that robotic reconstruction has emerged as a new standard of care, challenging the long-held position of open surgery as the gold standard. While open surgery remains an important option for specific cases, the growing body of evidence supports the increasing dominance of robotics in this field.

However, the contemporary literature on robotic ureteral reconstruction, while providing valuable insights, has notable limitations that warrant mentioning. Most of the studies included in this review had a retrospective study design, which inherently introduces biases and hinders the establishment of causal relationships. The small number of RCTs restricts the availability of high-quality evidence, limiting our understanding of how surgical outcomes from robotic ureteral reconstruction truly compare to laparoscopic and

open surgery. This is especially true as there is significant variability in the definitions of success employed across different studies. The need for standardized criteria for defining and measuring success in ureteral reconstruction studies across all surgical approaches hampers the ability to compare outcomes consistently, complicating the efforts to draw meaningful conclusions from the collective body of literature. Lastly, the predominance of small, single-institution cohorts within the current literature potentially challenges the generalizability of the results. This limitation underscores the need for more extensive, multi-center studies to bolster the external validity of research findings and enhance their applicability to a more comprehensive patient and surgeon population.

Furthermore, there are several areas within robotic ureteral reconstruction that warrant additional study, particularly newer techniques and technologies. Techniques such as the non-transecting side-to-side anastomosis and ureteroureterostomy (UU) for distal strictures are still in their early stages of adoption. Long-term studies evaluating their safety, efficacy, and success rates are necessary to establish their roles in ureteral reconstruction. Similarly, emerging technologies like the SP robotic platform remain underreported in the literature. While the SP system offers distinct advantages, including retroperitoneal access, the ability to work in confined spaces, and reduced postoperative pain, its role in ureteral reconstruction is uncertain. Currently, the SP system is primarily utilized in large academic centers, and its adoption is limited by a lack of widespread experience and supporting evidence. Future research should focus on evaluating the learning curve associated with the SP platform, comparing its outcomes to multiport robotic systems, and assessing its cost-effectiveness and impact on patient recovery. These efforts will help define the utility of these innovations and guide their integration into clinical practice.

Conclusion

Robotic ureteral reconstruction is a constantly evolving field. This review summarizes the growing body of evidence supporting the efficacy and safety of the robotic platform and highlights its many advantages over open and laparoscopic ureteral reconstructive surgery.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Author contributions

Rebeca Gonzalez Jauregui: Data curation; Investigation; Methodology; Writing – original draft; Writing – review & editing.

Rohan Bhalla: Conceptualization; Supervision; Writing – original draft; Writing – review & editing.

Karen Doersch: Supervision; Writing – review & editing.

Brian J. Flynn: Conceptualization; Supervision; Writing – original draft; Writing – review & editing.

Acknowledgements

Artwork by Avalon Swenson MD, University of Minnesota.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Competing interests

The authors declare that there is no conflict of interest.

Availability of data and materials

Not applicable.

ORCID iD

Rebeca Gonzalez Jauregui  <https://orcid.org/0009-0009-0445-1371>

References

1. Tyrirtzis SI and Wiklund NP. Ureteral strictures revisited. . .trying to see the light at the end of the tunnel: a comprehensive review. *J Endourol* 2015; 29(2): 124–136.
2. Drain A, Jun MS and Zhao LC. Robotic ureteral reconstruction. *Urol Clin North Am* 2021; 48(1): 91–101.
3. Yang K, Pang KH, Fan S, et al. Robotic ureteral reconstruction for benign ureteral strictures: a systematic review of surgical techniques, complications and outcomes. *BMC Urol* 2023; 23(1): 160.
4. Hebert KJ, Linder BJ, Gettman MT, et al. A contemporary analysis of ureteral reconstruction 30-day morbidity utilizing the national surgical quality improvement program database: comparison of minimally invasive vs open approaches. *J Endourol* 2022; 36(2): 209–215.
5. Leal Ghezzi T and Campos Corleta O. 30 Years of robotic surgery. *World J Surg* 2016; 40(10): 2550–2557.
6. Elkoushy MA and Andonian S. Surgical, radiologic, and endoscopic anatomy of the kidney and ureter. In: Partin AW, Dmochowski RR, Kavoussi LR, et al. (ed) *Campbell-Walsh-Wein Urology*, 12th ed. Philadelphia, PA: Elsevier, 2021.
7. Nakada SY and Best SL. Management of upper urinary tract obstruction. In: Partin AW, Dmochowski RR, Kavoussi LR, et al. (ed) *Campbell-Walsh-Wein urology*, 12th ed. Philadelphia, PA: Elsevier, 2021.
8. Vasudevan VP, Johnson EU, Wong K, et al. Contemporary management of ureteral strictures. *J Clin Urol* 2019; 12(1): 20–31.
9. Zappia JL, Farrow JM, Song L, et al. Outcomes of robot-assisted laparoscopic pyeloplasty based on degree of obstruction on preoperative Tc-99 MAG-3 renal scintigraphy. *J Endourol* 2023; 37(2): 151–156.
10. Lee Z, Asghar A, Koster H, et al. Ureteral rest is associated with improved outcomes in patients undergoing robotic ureteral reconstruction of proximal and middle ureteral strictures. *J Urol* 2020; 203: e824.
11. Asghar AM, Lee Z, Lee RA, et al. Robotic ureteral reconstruction in patients with radiation-induced ureteral strictures: experience from the collaborative of reconstructive robotic ureteral surgery. *J Endourol* 2021; 35(2): 144–150.
12. Kapogiannis F, Spartalis E, Fasoulakis K, et al. Laparoscopic and robotic management of ureteral stricture in adults. *In Vivo* 2020; 34(3): 965–972.
13. Khan F, Ahmed K, Lee N, et al. Management of ureteropelvic junction obstruction in adults. *Nat Rev Urol* 2014; 11(11): 629–638.
14. Colaco M, Caveney MK and Terlecki RP. Performance of adult pyeloplasty relative to endourological management in the era of robotic surgery: data from the nationwide inpatient sample. *Urol Pract* 2018; 5(2): 120–123.

15. Jacobs BL, Lai JC, Seelam R, et al. The comparative effectiveness of treatments for ureteropelvic junction obstruction. *Urology* 2018; 111: 72–77.
16. Jacobs BL, Lai JC, Seelam R, et al. Variation in the use of open pyeloplasty, minimally invasive pyeloplasty, and endopyelotomy for the treatment of ureteropelvic junction obstruction in adults. *J Endourol* 2017; 31(2): 210–215.
17. Lee M, Lee Z, Strauss D, et al. Multi-institutional experience comparing outcomes of adult patients undergoing secondary versus primary robotic pyeloplasty. *Urology* 2020; 145: 275–280.
18. Basatac C, Boylu U, Onol FF, et al. Comparison of surgical and functional outcomes of open, laparoscopic and robotic pyeloplasty for the treatment of ureteropelvic junction obstruction. *Turk J Urol* 2014; 40(1): 24–30.
19. Pahwa M, Pahwa AR, Girotra M, et al. Defining the pros and cons of open, conventional laparoscopy, and robot-assisted pyeloplasty in a developing nation. *Adv Urol* 2014; 2014: 850156.
20. Autorino R, Eden C, El-Ghoneimi A, et al. Robot-assisted and laparoscopic repair of ureteropelvic junction obstruction: a systematic review and meta-analysis. *Eur Urol* 2014; 65(2): 430–452.
21. Hanske J, Sanchez A, Schmid M, et al. Comparison of 30-day perioperative outcomes in adults undergoing open versus minimally invasive pyeloplasty for ureteropelvic junction obstruction: analysis of 593 patients in a prospective national database. *World J Urol* 2015; 33(12): 2107–2113.
22. Lamb BW, Vasdev N, Mourtzilas E, et al. Robotic pyeloplasty: Initial experience of a single UK centre. *J Clin Urol* 2015; 8(2): 127–131.
23. Chammas MF, Mitre AI, Arap MA, et al. Learning robotic pyeloplasty without simulators: an assessment of the learning curve in the early robotic era. *Clinics (Sao Paulo)* 2019; 74: e777.
24. Fan S, Xiong S, Li Z, et al. Pyeloplasty with the Kangduo surgical robot vs the da vinci si robotic system: preliminary results. *J Endourol* 2022; 36(12): 1538–1544.
25. Marien T, Bjurlin MA, Wynia B, et al. Outcomes of robotic-assisted laparoscopic upper urinary tract reconstruction: 250 consecutive patients. *BJU Int* 2015; 116(4): 604–611.
26. Masieri L, Sforza S, Di Maida F, et al. Robotic correction of iatrogenic ureteral stricture: preliminary experience from a tertiary referral centre. *Scand J Urol* 2019; 53(5): 356–360.
27. Dirie NI, Ahmed MA, Mohamed MA, et al. Robot-assisted laparoscopic pyeloplasty in adults: a comparison analysis of primary versus redo pyeloplasty in a single center. *Urol J* 2020; 18(1): 45–50.
28. Masieri L, Sforza S, Mari A, et al. Robot-assisted pyeloplasty for ureteropelvic junction obstruction: experience from a tertiary referral center. *Minerva Urol Nefrol* 2019; 71(2): 168–173.
29. Hopf HL, Bahler CD and Sundaram CP. Long-term outcomes of robot-assisted laparoscopic pyeloplasty for ureteropelvic junction obstruction. *Urology* 2016; 90: 106–110.
30. Wood TC, Raison N, El-Hage O, et al. Robot-assisted laparoscopic pyeloplasty: a single-centre experience. *Surg Endosc* 2018; 32(11): 4590–4596.
31. Popelin MB, Pinar U, Benamran D, et al. Functional outcomes after robot-assisted pyeloplasty for ureteropelvic junction obstruction: a bi-centre experience. *Int J Med Robot* 2021; 17(2): e2201.
32. Lee Z, Moore B, Giusto L, et al. Use of indocyanine green during robot-assisted ureteral reconstructions. *Eur Urol* 2015; 67(2): 291–298.
33. Carmona O, Dotan ZA, Haifler M, et al. Laparoscopic versus robot-assisted pyeloplasty in adults—a single-center experience. *J Pers Med* 2022; 12(10): 9.
34. Cheng S, Li X, Yang K, et al. Modified laparoscopic and robotic flap pyeloplasty for recurrent ureteropelvic junction obstruction with a long proximal ureteral stricture: the “wishbone” anastomosis and the “ureteral Plate” technique. *Urol Int* 2021; 105(7): 642–649.
35. Razavi S, Babbini J and Dahl DM. Outcomes of robotic-assisted pyeloplasty in symptomatic versus asymptomatic patients. *World J Urol* 2023; 41(7): 1959–1965.
36. Dirie NI, Ahmed MA and Wang S. Is secondary robotic pyeloplasty safe and effective as primary robotic pyeloplasty? a systematic review and meta-analysis. *J Robot Surg* 2020; 14(2): 241–248.
37. Light A, Karthikeyan S, Maruthan S, et al. Peri-operative outcomes and complications after laparoscopic vs robot-assisted dismembered pyeloplasty: a systematic review and meta-analysis. *BJU Int* 2018; 122(2): 181–194.
38. Di Gregorio M, Botnaru A, Bairy L, et al. Passing from open to robotic surgery for dismembered pyeloplasty: a single centre experience. *Springerplus* 2014; 3: 580.

39. Cheng S, Fan S, Wang J, et al. Laparoscopic and robotic ureteroplasty using onlay flap or graft for the management of long proximal or middle ureteral strictures: our experience and strategy. *Int Urol Nephrol* 2021; 53(3): 479–488.
40. Razavi S, Babbin J and Dahl D. Robot-assisted laparoscopic pyeloplasty is a valid option for ureteropelvic junction obstruction repair in adults with congenital renal abnormalities: a case series study. *BMC Urol* 2023 19; 23(1): 138.
41. Whiting D, Whitehurst L, Tsang D, et al. Retroperitoneal robotic-assisted laparoscopic pyeloplasty: a 10 year experience in a single institution. *J Endourol* 2022; 36(5): 615–619.
42. Jensen PH, Berg KD and Azawi NH. Robot-assisted pyeloplasty and pyelolithotomy in patients with ureteropelvic junction stenosis. *Scand J Urol* 2017; 51(4): 323–328.
43. Buffi NM, Lughezzani G, Fossati N, et al. Robot-assisted, single-site, dismembered pyeloplasty for ureteropelvic junction obstruction with the new da Vinci platform: a stage 2a study. *Eur Urol* 2015; 67(1): 151–156.
44. Heo JE, Kang SK, Lee J, et al. Outcomes of single-port robotic ureteral reconstruction using the da Vinci SP® system. *Investig Clin Urol* 2023; 64(4): 373–379.
45. Fiori C, Bertolo R, Manfredi M, et al. Robot-assisted laparoendoscopic single-site versus mini-laparoscopic pyeloplasty: a comparison of perioperative, functional and cosmetic results. *Minerva Urol Nefrol* 2017; 69(6): 604–612.
46. Ramanitharan M, Lalgudi Narayanan D, et al. Outcomes of robot-assisted ureterocalicostomy in secondary ureteropelvic junction in adults: initial experience using Da Vinci Xi system with near-infrared fluorescence imaging. *J Laparoendosc Adv Surg Tech A* 2020; 30(1): 48–52.
47. Sun G, Yan L, Ouyang W, et al. Management for ureteral stenosis: a comparison of robot-assisted laparoscopic ureteroureterostomy and conventional laparoscopic ureteroureterostomy. *J Laparoendosc Adv Surg Tech A* 2019; 29(9): 1111–1115.
48. Hamamoto S, Taguchi K, Kawase K, et al. Efficacy of robot-assisted ureteroureterostomy in patients with complex ureteral stricture after ureteroscopic lithotripsy. *J. Clin. Med* 2023; 12(24): 7726.
49. Yang KVK, Asghar AM, Lee RDA, et al. Robot-assisted laparoscopic distal ureteroureterostomy for distal benign ureteral strictures with long-term follow-up. *J Endourol* 2022; 36(2): 203–208.
50. Buffi NM, Lughezzani G, Hurle R, et al. Robot-assisted surgery for benign ureteral strictures: experience and outcomes from four tertiary care institutions. *Eur Urol* 2017; 71(6): 945–951.
51. Lee M, Lee Z, Koster H, et al. Intermediate-term outcomes after robotic ureteral reconstruction for long-segment (≥ 4 centimeters) strictures in the proximal ureter: a multi-institutional experience. *Investig Clin Urol* 2021; 62(1): 65–71.
52. Lee M, Lee Z, Houston N, et al. Robotic ureteral reconstruction for recurrent strictures after prior failed management. *BJUI Compass* 2023; 4(3): 298–304.
53. Xiong S, Wang J, Zhu W, et al. Onlay repair technique for the management of ureteral strictures: a comprehensive review. *Biomed Res Int* 2020; 2020: 6178286.
54. Fan S, Li Z, Meng C, et al. Robotic versus laparoscopic ureteroplasty with a lingual mucosa graft for complex ureteral stricture. *Int Urol Nephrol* 2023; 55(3): 597–604.
55. Lee Z, Lee M, Koster H, et al. A multi-institutional experience with robotic ureteroplasty with buccal mucosa graft: an updated analysis of intermediate-term outcomes. *Urology* 2021; 147: 306–310.
56. Yang K, Fan S, Wang J, et al. Robotic-assisted lingual mucosal graft ureteroplasty for the repair of complex ureteral strictures: technique description and the medium-term outcome. *Eur Urol* 2022; 81(5): 533–540.
57. Packiam VT, Cohen AJ, Nottingham CU, et al. Open Vs minimally invasive adult ureteral reimplantation: analysis of 30-day outcomes in the national surgical quality improvement program (NSQIP) database. *Urology* 2016; 94: 123–128.
58. Elsamra SE, Theckumparampil N, Garden B, et al. Open, laparoscopic, and robotic ureteroneocystostomy for benign and malignant ureteral lesions: a comparison of over 100 minimally invasive cases. *J Endourol* 2014; 28(12): 1455–1459.
59. Carbonara U, Branche B, Cisu T, et al. Robot-assisted ureteral reimplantation: a single-center comparative study. *J Endourol* 2021; 35(10): 1504–1511.
60. Skupin PA, Stoffel JT, Malaeb BS, et al. Robotic versus open ureteroneocystostomy: is there a robotic benefit? *J Endourol* 2020; 34(10): 1028–1032.
61. Zhang Y, Ouyang W, Xu H, et al. A comparison of robot-assisted laparoscopic ureteral reimplantation and conventional laparoscopic

- ureteral reimplantation for the management of benign distal ureteral stricture. *Urol J* 2020 16; 17(3): 252–256.
62. Stolzenburg JU, Rai BP, Do M, et al. Robot-assisted technique for Boari flap ureteric reimplantation: replicating the techniques of open surgery in robotics. *BJU Int* 2016; 118(3): 482–484.
63. Corse TD, Dayan L, Cheng N, et al. A multi-institutional experience utilizing boari flap in robotic urinary reconstruction. *J Endourol* 2023; 37(7): 775–780.
64. Dell'Oglio P, Palagonia E, Wisz P, et al. Robot-assisted boari flap and psoas hitch ureteric reimplantation: technique insight and outcomes of a case series with ≥ 1 year of follow-up. *BJU Int* 2021 1; 128(5): 625–33.
65. Do M, Kallidonis P, Qazi H, et al. Robot-assisted technique for boari flap ureteral reimplantation: is robot assistance beneficial? *J Endourol* 2014; 28(6): 679–685.
66. Slawin J, Patel NH, Lee Z, et al. Ureteral reimplantation via robotic nontransecting side-to-side anastomosis for distal ureteral stricture. *J Endourol* 2020; 34(8): 836–839.
67. Kushwaha SS, Kalra S, Dorairajan LN, et al. Robot-assisted complex urinary tract reconstruction using intestinal segments: redefining the paradigm. *J Robotic Surg* 2023; 17(3): 1113–1123.
68. Fan S, Han G, Li Z, et al. Robot-assisted laparoscopic ileal ureter replacement with extracorporeal ileal segment preparation for long ureteral strictures: a case series. *BMC Surg* 2022; 22(1): 435.
69. Yang K, Wang X, Xu C, et al. Totally intracorporeal robot-assisted unilateral or bilateral ileal ureter replacement for the treatment of ureteral strictures: technique and outcomes from a single center. *Eur Urol* 2023; 84(6): 561–570.
70. Zhu W, Xiong S, Fang D, et al. Minimally invasive ileal ureter replacement: comparative analysis of robot-assisted laparoscopic versus conventional laparoscopic surgery. *Int J Med Robot* 2021; 17(3): e2230.
71. Jun MS, Stair S, Xu A, et al. A multi-institutional experience with robotic appendiceal ureteroplasty. *Urology* 2020; 145: 287–291.
72. Wang J, Li Z, Fan S, et al. Robotic ureteroplasty with appendiceal onlay flap: an update on the outcomes of 18-month follow-up. *Transl Androl Urol* 2022; 11(1): 209–229.
73. Wang J, Zhang B, Fan J, et al. The application of the “omental wrapping” technique with autologous onlay flap/graft ureteroplasty for the management of long ureteral strictures. *Transl Androl Urol* 2021; 10(7): 2871–2878.
74. Breda A, Diana P, Territo A, et al. Intracorporeal versus extracorporeal robot-assisted kidney autotransplantation: experience of the ERUS RAKT working group. *Eur Urol* 2022; 81(2): 168–175.
75. Kaouk J, Chavali JS, Ferguson E, et al. Single port robotic kidney autotransplantation: initial case series and description of technique. *Urology* 2023; 176: 87–93.
76. Kwong J, Schiefer D, Aboalsamh G, et al. Optimal management of distal ureteric strictures following renal transplantation: a systematic review. *Transpl Int* 2016; 29(5): 579–588.
77. Gin GE, Ruel NH, Parihar JS, et al. Ureteroenteric anastomotic revision as initial management of stricture after urinary diversion. *Int J Urol* 2017; 24(5): 390–395.
78. Lee Z, Sterling ME, Keehn AY, et al. The use of indocyanine green during robotic ureteroenteric reimplantation for the management of benign anastomotic strictures. *World J Urol* 2019; 37(6): 1211–1216.
79. Tuderti G, Brassetti A, Minisola F, et al. Transnephrostomic indocyanine green-guided robotic ureteral reimplantation for benign ureteroileal strictures after robotic cystectomy and intracorporeal neobladder: step-by-step surgical technique, perioperative and functional outcomes. *J Endourol* 2019; 33(10): 823–828.
80. Albisinni S, Aoun F, Mjaess G, et al. Contemporary management of benign ureteroenteric strictures after cystectomy: a systematic review. *Minerva Urol Nephrol* 2021; 73(6): 724–730.